Dupixent is a medication developed for the treatment of various chronic inflammatory conditions, including asthma, eczema, and chronic rhinosinusitis with nasal polyps. It contains the active ingredient dupilumab, which is a monoclonal antibody that works by inhibiting specific pathways in the immune system. This mechanism helps to reduce inflammation and alleviate symptoms associated with these conditions.
The drug is administered via subcutaneous injection and is typically prescribed for patients who have not responded adequately to other treatments. Dupixent has been studied in clinical trials and has received regulatory approval in several countries for its effectiveness in managing symptoms and improving the quality of life for patients with these chronic conditions.
Dupixent is part of a growing class of biologic therapies that target specific components of the immune system, offering an alternative for patients who may not benefit from traditional therapies. Its introduction has contributed to advancements in the management of chronic inflammatory diseases, providing new options for both patients and healthcare providers.